New mRNA shingles vaccine shows promise in early trial
NCT ID NCT06375512
First seen Apr 04, 2026 · Last updated May 21, 2026 · Updated 7 times
Summary
This study tested a new mRNA vaccine called IN001 to prevent shingles in 150 healthy adults aged 50 to 69. The main goals were to check the vaccine's safety and how well it triggers the immune system. Researchers measured side effects and antibody levels to see if the vaccine works as intended.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HERPES ZOSTER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CenExel
Hollywood, Florida, 33024, United States
-
Emeritus Research Pty Ltd
Sydney, New South Wales, 2019, Australia
-
Emeritus Research Pty Ltd
Melbourne, Victoria, 3124, Australia
Conditions
Explore the condition pages connected to this study.